Inventory

3 Months Ended

Mar. 31, 2019

Inventory Disclosure [Abstract]

Inventory

(4) Inventory

The Company capitalizes its purchases of saleable inventory of Vascepa from suppliers that have been qualified by the FDA. Inventories as of March 31, 2019 and December 31, 2018 consist of the following:

In thousands	March 31, 2019			December 31, 2018
Raw materials	$	7,941		$	14,142
Work in process		8,653			8,590
Finished goods		41,473			35,357
Total inventory, gross		58,067			58,089
Inventory cost adjustment		(158	)		(287	)
Inventory	$	57,909		$	57,802